The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Changes in levels of cartilage oligomeric proteinase and urinary C-terminal telopeptide of type II collagen in subjects with knee osteoarthritis after dextrose prolotherapy: A randomized controlled trial
Open accessAbstract
OBJECTIVE: To assess the effects of dextrose prolotherapy in patients with knee osteoarthritis on the levels of serum cartilage oligomeric proteinase and urinary C-terminal telopeptide of type II collagen, and on the Western Ontario McMaster Universities Index and numerical rating scale score for pain. METHODS: A randomized controlled trial, in which participants were randomly allocated into 2 groups, receiving injections of either hyaluronic acid or dextrose prolotherapy. The hyaluronic acid group received 5 injections, 1 each on weeks 1, 2, 3, 4 and 5, and the dextrose prolotherapy group received 3 injections, 1 each on weeks 1, 5 and 9. Serum cartilage oligomeric proteinase, urinary C-terminal telopeptide of type II collagen, Western Ontario McMaster Universities Index score, and numerical rating scale score for pain were measured at baseline and 3 weeks after the last injection. Comparative analysis was conducted using Wilcoxon test within groups and analysis of covariance (ANCOVA) test between groups. RESULTS: A total of 47 participants (21 allocated to hyaluronic acid, 26 allocated to dextrose prolotherapy) completed the protocol. Both interventions resulted in significant improvements in numerical rating scale scores for pain, total Western Ontario McMaster Universities Index scores, and its subscales score. However, the dextrose prolotherapy outperformed hyaluronic acid in numerical rating scale score for pain and level of urinary C-terminal telopeptide of type II collagen, with score changes differences of 0.93 (p = 0.042) and 0.34 (p = 0.048), respectively. No significant changes in level of serum cartilage oligomeric proteinase were found in either group. CONCLUSION: Dextrose prolotherapy is an alternative injection therapy for knee osteoarthritis, which was found to be associated with a significant reduction in urinary C-terminal telopeptide of type II collagen compared with hyaluronic acid injection. Neither injection method resulted in reduced serum cartilage oligomeric proteinase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies suggest that intra-articular dextrose prolotherapy may provide superior pain relief and cartilage protection compared to hyaluronic acid injections, though further research is needed to confirm long-term benefits [94].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The burden of musculoskeletal conditions at the start of the new millennium.
(2003) · PubMed · Cited by 595
Hootman, J. M., Helmick, C. G., Barbour, K. E., Theis, K. A., & Boring, M. A. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39692 · Cited by 581
Altman, R., Manjoo, A., Fierlinger, A., Niazi, F., & Nicholls, M. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0775-z · Cited by 486 · cited 1×
“This leads to inhibition of IL-1β expression by inducing mitogen-activated protein kinase phosphatase (MKP)-1, eventually decreasing the production of catabolic enzymes (MMP 1, 2, 3, 9, and 13) that has been known to induce inflammation in the synovium (36, 37).”
BackgroundValue of biomarkers in osteoarthritis: current status and perspectives
Lotz, M., Martel-Pelletier, J., Christiansen, C., Brandi, M.-L., Bruyère, O., Chapurlat, R., Collette, J., Cooper, C., Giacovelli, G., Kanis, J. A., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203726 · Cited by 328 · cited 3×
“The uCTX-II level is one of several cartilage degradation biomarkers, wherein increased levels of uCTX-II correlate with radiological severity and cartilage thinning on magnetic resonance imaging (MRI) examination (14, 21, 22).”
BackgroundThe Impact of Osteoarthritis in the United States: A Population-Health Perspective
Murphy, L., & Helmick, C. G. (2012) · AJN, American Journal of Nursing · doi:10.1097/01.naj.0000412646.80054.21 · Cited by 252
A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain
Hauser, R. A., Lackner, J. B., Steilen-Matias, D., & Harris, D. K. (2016) · Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders · doi:10.4137/cmamd.s39160 · Cited by 247 · cited 1×
“And while the chondrogenic effects of prolotherapy remain unclear, several in vitro studies have shown that human cells produce various growth factors after exposure to hypertonic dextrose (23).”
BackgroundProlotherapy in Primary Care Practice
Rabago, D., Slattengren, A., & Zgierska, A. (2010) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2009.09.013 · Cited by 241 · cited 1×
“An example of a currently developing regenerative approach is prolotherapy, an injection-based modality for treating chronic musculoskeletal pain through the use of substances such as dextrose, phenol-glycerine-glucose (P2G), or sodium morrhuate (9).”
BackgroundCartilage oligomeric matrix protein: COMPopathies and beyond
Posey, K. L., Coustry, F., & Hecht, J. T. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.023 · Cited by 221 · cited 1×
“However, COMP elevation is not specific to knee OA; some studies have shown that sCOMP level can increase in joint trauma or excessive physical activity (28, 29).”
Backgroundvan Spil, W. E., DeGroot, J., Lems, W. F., Oostveen, J. C. M., & Lafeber, F. P. J. G. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.01.012 · Cited by 207 · cited 1×
“COMP and uCTX-II are recommended as promising specific biomarkers in OA cases based on Burden of disease, Investigative, prognostic, efficacy of intervention, and diagnostic (BIPED) criteria, as stated in a systematic review (16).”
BackgroundReeves, K. D., & Hassanein, K. M. (2000) · PubMed · Cited by 195
Dextrose Prolotherapy for Knee Osteoarthritis: A Randomized Controlled Trial
Rabago, D., Patterson, J. J., Mundt, M., Kijowski, R., Grettie, J., Segal, N. A., & Zgierska, A. (2013) · The Annals of Family Medicine · doi:10.1370/afm.1504 · Cited by 191 · cited 2×
“85) , which exceeded the minimal clinically important difference (MCID) on the WOMAC for knee OA, which is 12 points (12).”
BackgroundMethodPrognostic biomarkers in osteoarthritis
Attur, M., Krasnokutsky-Samuels, S., Samuels, J., & Abramson, S. B. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835a9381 · Cited by 178 · cited 1×
“The uCTX-II level is one of several cartilage degradation biomarkers, wherein increased levels of uCTX-II correlate with radiological severity and cartilage thinning on magnetic resonance imaging (MRI) examination (14, 21, 22).”
BackgroundHosnijeh, F. S., Siebuhr, A. S., Uitterlinden, A. G., Oei, E. H. G., Albert Hofman, D., Karsdal, M. A., Bierma‐Zeinstra, S., Bay‐Jensen, A., & van Meurs, J. B. J. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0976-3 · Cited by 128 · cited 1×
“cartilage (14) and is a promising biomarker of cartilage damage, which can be used for early detection and assessment of disease progression (26, 27).”
BackgroundProlotherapy: A Clinical Review of Its Role in Treating Chronic Musculoskeletal Pain
Distel, L. M. L., & Best, T. M. (2011) · PM&R · doi:10.1016/j.pmrj.2011.04.003 · Cited by 126 · cited 1×
“Meanwhile, the pain reduction mechanism in prolotherapy is assumed to occur by its capacity to promote growth-factor mediated tissue healing (38, 39), provide desirable nutrients necessary for regeneration (38), exert a potential direct effect on peripheral nerves (39), and strengthen the ligament and tendons, which h…”
Effectiveness and utility of hyaluronic acid in osteoarthritis
Migliore, A. (2015) · Clinical Cases in Mineral and Bone Metabolism · doi:10.11138/ccmbm/2015.12.1.031 · Cited by 126 · cited 1×
“This leads to inhibition of IL-1β expression by inducing mitogen-activated protein kinase phosphatase (MKP)-1, eventually decreasing the production of catabolic enzymes (MMP 1, 2, 3, 9, and 13) that has been known to induce inflammation in the synovium (36, 37).”
BackgroundRahimzadeh, P., Imani, F., Faiz, S. H. R., Entezary, S. R., Zamanabadi, M. N., & Alebouyeh, M. R. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s147757 · Cited by 121 · cited 1×
“Regenerative therapy is an alternative approach that has been considered for OA, due to its potential to aid tissue regeneration, improve clinical manifestations, and repair damaged tissue structure, which is the underlying pathological condition in OA (8).”
BackgroundLEIGHTON, R. K., Åkermark, C., Therrien, R., Richardson, J., Andersson, M., Todman, M. G., & Arden, N. (2013) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2013.10.009 · Cited by 109
Long-term effects of dextrose prolotherapy for anterior cruciate ligament laxity.
Reeves, K. D., & Hassanein, K. M. (2003) · PubMed · Cited by 108
Dechellis, D. M., & Cortazzo, M. H. (2011) · Techniques in Regional Anesthesia and Pain Management · doi:10.1053/j.trap.2011.05.002 · Cited by 103 · cited 1×
“Other studies stipulate that the injected proliferant imitates the natural healing process of the body through initiation of a local inflammatory cascade, which triggers the release of growth factors and collagen deposition (24, 25).”
BackgroundTrojian, T. H., Concoff, A. L., Joy, S. M., Hatzenbuehler, J. R., Saulsberry, W. J., & Coleman, C. I. (2016) · British Journal of Sports Medicine · doi:10.1136/bjsports-2015-095683 · Cited by 90 · cited 1×
“Several studies have demonstrated the effectiveness of hyaluronic acid (HA) injections, and recent guidelines have recommended their use in knee OA (4, 5).”
BackgroundTopol, G. A., Podestá, L. A., Reeves, K. D., Giraldo, M. M., Johnson, L. L., Grasso, R., Jamín, A., Clark, T. J., & Rabago, D. (2016) · PM&R · doi:10.1016/j.pmrj.2016.03.008 · Cited by 88 · cited 2×
“(13), through observation using arthroscopy.”
ResultLiu, T., Liu, X.-S., Zhang, M., Liu, X.-N., Zhu, F., Zhu, F., Ouyang, S., Li, S., Song, C., Sun, H., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2626-4 · Cited by 86 · cited 1×
“In addition, increased sCOMP level is also found in malignancies of the breast, prostate, and colon (30, 31).”
BackgroundSit, R. W. S., Wu, R. W. K., Rabago, D., Reeves, K. D., Chan, D. C. C., Yip, B. H. K., Chung, V. C., & Wong, S. Y. S. (2020) · The Annals of Family Medicine · doi:10.1370/afm.2520 · Cited by 79
Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis
Wisłowska, M., & Jabłońska, B. (2004) · Clinical Rheumatology · doi:10.1007/s10067-004-1000-x · Cited by 78 · cited 1×
“cartilage (14) and is a promising biomarker of cartilage damage, which can be used for early detection and assessment of disease progression (26, 27).”
BackgroundAltman, R. D., Rosen, J. E., Bloch, D. A., & Hatoum, H. T. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2011.07.001 · Cited by 77
Republished: Value of biomarkers in osteoarthritis: current status and perspectives
Lotz, M., Pelletier, J., Christiansen, C., Brandi, M. L., Bruyère, O., Chapurlat, R. D., Collette, J., Cooper, C. C., Giacovelli, G., Kanis, J. А., et al. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-203726rep · Cited by 75
Jevsevar, D. S., Shores, P. B., Mullen, K. J., Schulte, D. M., Brown, G. A., & Cummins, D. S. (2018) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-17-00318 · Cited by 71 · cited 1×
“In contrast to these findings, however, a meta-analysis concluded that treatment of knee OA with HA injection did not result in a significantly different outcome from intra-articular placebo, despite the higher costs compared with other common non-operative intra-articular modalities (7).”
ResultBedi, A., Lynch, E. B., Enselman, E. R. S., Davis, M. E., DeWolf, P. D., Makki, T. A., Kelly, B. T., Larson, C. M., Henning, P. T., & Mendias, C. L. (2013) · The American Journal of Sports Medicine · doi:10.1177/0363546513499308 · Cited by 59 · cited 1×
“However, COMP elevation is not specific to knee OA; some studies have shown that sCOMP level can increase in joint trauma or excessive physical activity (28, 29).”
BackgroundUse of biochemical markers to study and follow patients with osteoarthritis
Garnero, P. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0023-5 · Cited by 50 · cited 1×
“The uCTX-II level is one of several cartilage degradation biomarkers, wherein increased levels of uCTX-II correlate with radiological severity and cartilage thinning on magnetic resonance imaging (MRI) examination (14, 21, 22).”
BackgroundConrozier, T., Balblanc, J., Richette, P., Mulleman, D., Maillet, B., Henrotin, Y. E., Rannou, F., Piroth, C., Hilliquin, P., Mathieu, P., et al. (2011) · Journal of Orthopaedic Research® · doi:10.1002/jor.21580 · Cited by 47 · cited 1×
“In contrast, previous studies showed either an increase (19) or decrease (20) in uCTX-II level following HA intervention.”
ResultLee, B., Yang, S., Kwon, S.-W., Choi, K. M., & Kim, W. (2019) · Journal of Rehabilitation Medicine · doi:10.2340/16501977-2561 · Cited by 47 · cited 1×
“These characteristics of the participants are known as the risk factors of knee OA based on previous study (17).”
BackgroundHenrotin, Y., Bannuru, R. R., Malaise, M., Ea, H., Confavreux, C. B., Bentin, J., Urbin-Choffray, D., Conrozier, T., Brasseur, J.-P., Thomas, P., et al. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2667-0 · Cited by 45 · cited 1×
“Meanwhile, decrease in levels of both biomarkers has been assumed which indicates the improvement in cartilage (15).”
BackgroundSert, A. T., Şen, E. İ., Esmaeilzadeh, S., & Ozcan, E. E. (2020) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2019.0335 · Cited by 42
Goswami, A. (2012) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2012.734900 · Cited by 36
Παπαδάκος, Κ. Σ., Darlix, A., Jacot, W., & Blom, A. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01141 · Cited by 28 · cited 1×
“In addition, increased sCOMP level is also found in malignancies of the breast, prostate, and colon (30, 31).”
BackgroundGonzalez-Fuentes, A. M., Green, D. M., Rossen, R. D., & Ng, B. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1376-8 · Cited by 21 · cited 1×
“In contrast, previous studies showed either an increase (19) or decrease (20) in uCTX-II level following HA intervention.”
ResultStrand, V., Lim, S., & Takamura, J. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1101-0 · Cited by 20
Lyftogt, J. (2008) · Australasian musculoskeletal medicine · Cited by 15
Xin, Y., Jianhao, L., Tian-sheng, S., Yongqiang, H., Weimin, F., Chen, M., Tiezheng, S., Jianhua, Y., Liang, X., Xiaoyuan, G., et al. (2015) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12782 · Cited by 10
Altman, R. D., Rosen, J. E., Bloch, D. A., & Hatoum, H. T. (2011) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(11)60339-7 · Cited by 9
Henrotin, Y., Bannuru, R. R., Malaise, M., Ea, H., Confavreux, C. B., Bentin, J., Urbin-Choffray, D., Conrozier, T., Brasseur, J.-P., Thomas, P., et al. (2018) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2018.02.582 · Cited by 5
Research works printed but not linked: 2
- [25]DeChellis DM, Cortazzo MH. Regenerative medicine in the field of pain medicine: Prolotherapy, platelet-rich plasma therapy, and stem cell therapy – theory and evidence. Tech Reg Anesth Pain Manag 2011; 15: 74– 80.
- [38]Banks AR. A Rationale for prolotherapy. J Orthop Med 1991; 13: 1– 12.
Cited by
Efficacy of Prolotherapy for Osteoarthritis: A Systematic Review
Waluyo, Y., Artika, S. R., Wahyuni, I. N., Gunawan, A. M. A. K., & Zainal, A. T. F. (2023) · Journal of Rehabilitation Medicine · doi:10.2340/jrm.v55.2572 · Cited by 50
“In the control group, there were 5 studies comparing prolotherapy with saline (10, 11, 18–20), 3 studies compared prolotherapy with exercise intervention (10, 11, 15), 3 studies compared prolotherapy with intra-articular injections of hyaluronic acid (HA) (13, 14, 16), 2 studies compared prolotherapy with platelet-ric…”
BackgroundMethodResultInfluentialSelf-citationIntra-articular Therapies for Knee Osteoarthritis: Current Update
Oo, W. M., & Hunter, D. J. (2023) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-023-00207-x · Cited by 29
Goulian, A. J., Goldstein, B., & Saad, M. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062061 · Cited by 25
“Some studies suggest that intra-articular dextrose prolotherapy may provide superior pain relief and cartilage protection compared to hyaluronic acid injections, though further research is needed to confirm long-term benefits [94].”
Migliorini, F., Maffulli, N., Nijboer, C. H., Pappalardo, G., Pasurka, M., Betsch, M., & Kubach, J. (2025) · Biomedicines · doi:10.3390/biomedicines13010175 · Cited by 24
Vázquez, P. I. A., Tovilla‐Zárate, C. A., Castillo-Ávila, R. G., Legorreta-Ramírez, B. G., López‐Narváez, M. L., Arcila-Novelo, R., & González‐Castro, T. B. (2021) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001918 · Cited by 21
“Waluyo et al.28 reported that all participants had mild to moderate postinjection pain within 2–3 days.”
BackgroundResultInfluential
Metadata
- Authors
- Waluyo, Y., Budu, Bukhari, A., Adnan, E., Darjanti Haryadi, R., Idris, I., Hamid, F., Usman, A., Phetrus Johan, M., & Alfian Zainuddin, A.
- Affiliations
- Hasanuddin University (ID)
- Corresponding author
- Waluyo, Yose
- Venue
- Journal of Rehabilitation Medicine
- Publisher
- Medical Journals Sweden AB
- Published
- 2021-05-24
- Volume
- 53
- Issue
- 5
- Pages
- 1-7
- ISSN
- 1650-1977 (ISSN-L)
- 1651-2081
- PMC
- PMC8814831
- OpenAlex
- W3159236531
- Cited by
- 21
- References
- 41
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 1
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Rehabilitation Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Universitas Hasanuddin
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Tendon Structure and Treatment
- Keywords
- knee osteoarthritis, dextrose prolotherapy, hyaluronic acid injection, CTX-II, cartilage degradation biomarkers, pain, functional disability, injection therapy
- MeSH terms
- Prolotherapy, Double-Blind Method, Female, Glucose, Humans, Injections, Intra-Articular, Male, Middle Aged, Peptides, Treatment Outcome, Osteoarthritis, Knee, Collagen Type I, Collagen Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
